A Gut Microbe’s Bile Acid Could Make Cancer Immunotherapy Work for More Patients

Only 10 to 20 percent of people with gastrointestinal cancers respond to checkpoint immunotherapy, the class of drugs that tries to release the immune system's brakes on tumor cells. That gap has puzzled oncologists for years, and a growing body of research points toward the gut microbiome as a key variable. A new study published in Cell Reports Medicine now offers a specific candidate: Lactobacillus salivarius, a bacterium found more abundantly in patients who respond to therapy, appears to work through a bile acid metabolite called chenodeoxycholic acid (CDCA) that reshapes the immune environment inside tumors.

Key takeaways:

• L. salivarius was enriched in immunotherapy responders among 278 GI cancer patients, and its metabolite CDCA replicated the immune benefits in mouse tumor models.
• CDCA appears to work through two coordinated mechanisms: triggering immunogenic cell death in tumor cells and reprogramming suppressive macrophages into tumor-fighting ones.
• Higher plasma CDCA levels correlated with longer progression-free survival in responders, though this is an association, not proof of causation.
• This research is early-stage; the findings need validation in larger clinical trials before CDCA could be considered an adjunct therapy.

Lactobacillus salivarius is enriched in GI cancer immunotherapy responders

Lactobacillus salivarius emerged as the most prominently enriched bacterial species in patients who responded to immunotherapy, identified through metagenomic sequencing of stool samples from 278 gastrointestinal cancer patients. GI cancers, including colorectal and gastric cancer, account for 23.6% of new cancer cases and 34.2% of cancer-related deaths globally, according to the study, so even a modest improvement in immunotherapy response rates could affect hundreds of thousands of patients each year.

Prior research has already shown that Ligilactobacillus salivarius strains can suppress colon cancer cell growth in mouse models of colitis-associated cancer, and earlier work found that oral Lactobacillus salivarius reduced colon cancer incidence in chemically induced rat carcinogenesis. This new study goes further by connecting the bacterium's clinical association with a specific molecular mechanism.

When mice bearing syngeneic colorectal tumors (MC38 cell line) were given L. salivarius alongside anti-PD-1 therapy, tumor volume and weight fell significantly compared with anti-PD-1 alone. The bacterium's conditioned medium also directly inhibited tumor cell viability and clonogenic potential without harming normal GI epithelial cells, which is a meaningful early signal.

Why GI cancer patients with low immunotherapy response rates should care

Checkpoint inhibitors work by blocking the PD-1 and PD-L1 proteins that tumors exploit to hide from immune attack. The problem is that GI cancer immunotherapy efficacy remains modest on its own: that 10 to 20 percent objective response rate means the majority of patients treated with these expensive, sometimes toxic drugs see little benefit. Resistance is partly driven by the tumor microenvironment (TME), the ecosystem of immune and stromal cells surrounding a tumor.

Within the TME, tumor-associated macrophages (TAMs) are a central obstacle. Macrophages are plastic cells that can adopt either an antitumor M1 phenotype or a pro-tumor M2 phenotype. M2-polarized TAMs secrete immunosuppressive signals, including interleukin-10 and TGF-beta, that blunt the ability of CD8-positive T cells (the immune system's primary cancer killers) to function. Patients whose tumors are rich in M2 TAMs tend to respond poorly to anti-PD-1 therapy. A strategy that could tip that balance toward M1 macrophages while simultaneously activating CD8 T cells would be a meaningful advance, and that is exactly what CDCA appeared to do in this research.

How the team traced L. salivarius benefits to a single bile acid metabolite

Untargeted metabolomics, a broad chemical profiling technique, identified chenodeoxycholic acid as the compound consistently enriched in L. salivarius-conditioned medium, in the plasma of gavaged mice, and in the plasma of human immunotherapy responders. Lactobacillus species carry bile salt hydrolase (BSH) enzymes that strip amino acid conjugates from bile acids like glycochenodeoxycholic acid and taurochenodeoxycholic acid, releasing free CDCA. That enzymatic step appears to be the mechanistic bridge between the bacterium and the immune effects observed.

The researchers used advances in cancer microbiome research methodology, including syngeneic mouse models, flow cytometry of tumor-infiltrating immune cells, single-cell RNA sequencing, and in vivo depletion experiments, to trace the chain from bacterium to metabolite to immune outcome. Depleting either CD8 T cells or macrophages in mice abolished CDCA's antitumor benefit, confirming that both cell types are necessary, not just correlated.

What CDCA actually does inside the tumor microenvironment

CDCA appears to act on two fronts simultaneously. Inside tumor cells, it activates a branch of the endoplasmic reticulum (ER) stress response called the GRP78-PERK-eIF2alpha pathway, triggering immunogenic cell death (ICD): a form of cell death that releases tumor-associated antigens and danger signals (damage-associated molecular patterns, or DAMPs) that prime the immune system. CDCA treatment significantly increased extracellular ATP release and surface exposure of calreticulin, both established functional markers of ICD.

In macrophages, CDCA depolarized mitochondrial membranes, raised intracellular reactive oxygen species (ROS), and activated the ROS-NF-kappaB signaling axis. This cascade downregulated M2 signature genes including Mrc1, Arg-1, and Chi3l3, while upregulating M1 markers like Il1b, Nos2, and Il6. CDCA-reprogrammed TAMs then enabled CD8 T cells in co-culture to kill tumor cells more effectively and secrete more interferon-gamma and granzyme B, the proteins T cells use to destroy targets.

Bile acids broadly are not new to immunology. Research on bile acids and immune regulation has established that gut microbiota-modified bile acids influence both innate and adaptive immune cell differentiation, and CDCA specifically has been studied for its roles in gut barrier function and inflammation regulation. What is new here is the direct connection to tumor macrophage reprogramming and checkpoint immunotherapy synergy.

Open questions about CDCA's mechanism and clinical readiness

The study's authors are candid about what remains unresolved. The precise molecular mechanism by which CDCA generates mitochondrial ROS in macrophages has not been fully defined. More critically, L. salivarius has not yet been genetically confirmed as the direct cellular source of CDCA in the human gut: that would require manipulating the bacterium's BSH biosynthetic pathway and showing the effect disappears, work the team identifies as a necessary next step. The challenges of microbiota-based immunotherapy research are substantial, including accurately capturing microbial diversity and attributing causation rather than correlation.

The clinical data here is associative: higher plasma CDCA correlated with longer progression-free survival in responders, but a correlation in 278 patients is not a randomized trial. Validation in larger, prospective clinical cohorts is explicitly listed as a requirement before CDCA could be used as an adjuvant to immunotherapy.

Common Questions

Can taking a probiotic with L. salivarius improve GI cancer treatment outcomes? Not based on current evidence. The clinical finding is an association between naturally higher L. salivarius abundance and better immunotherapy response; no trial has tested deliberate L. salivarius supplementation in GI cancer patients. It would be premature to supplement on the basis of this research.

Is CDCA a supplement or drug you can take now? CDCA is an FDA-approved drug (obeticholic acid is a derivative used in liver disease), so it has an established safety profile, but it has not been tested as a cancer immunotherapy adjuvant in humans. The mouse results are encouraging but not yet translatable to a clinical recommendation.

Which GI cancers does this research cover? The patient cohort included multiple gastrointestinal cancer types. The mouse models focused on colorectal cancer (CRC) and gastric cancer (GC), the two GI cancers where anti-PD-1 therapy already has regulatory approval in some settings.

Does this mean my microbiome affects how well immunotherapy works? Emerging evidence increasingly suggests yes, though the specific bacteria and mechanisms vary by cancer type and patient. This study adds a specific bacterium-metabolite-immune pathway to that picture, but it is one piece of a complex puzzle that researchers are still assembling.

References

1. Bohan Zhang, Yifan Zhang, Yi Cai, et al. (2026). Lactobacillus salivarius potentiates gastrointestinal cancer immunotherapy through its metabolite chenodeoxycholic acid. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2026.103009
2. Wenhong Yang, Tao Li, Shixiang An, et al. (2025). Ligilactobacillus salivarius LZZAY01 accelerated autophagy and apoptosis in colon cancer cells and improved gut microbiota in CAC mice. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01861-24
3. Effects of Lactobacillus salivarius Ren on cancer prevention and intestinal microbiota in 1, 2-dimethylhydrazine-induced rat model. NIH. https://pubmed.ncbi.nlm.nih.gov/26025172/
4. Supriya Peshin, Faizan Bashir, Naga Anvesh Kodali, et al. (2025). Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications. Antibodies. https://doi.org/10.3390/antib14030058
5. Sumeed Syed Manzoor, Annemiek Doedens, Michael B. Burns (2020). The promise and challenge of cancer microbiome research. Genome Biology. https://doi.org/10.1186/s13059-020-02037-9
6. Xiaomin Su, Yunhuan Gao, Rongcun Yang (2023). Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1127743
7. Yangshuo Li, Kaili Wang, Jie Ding, Shuai Sun, Zhexin Ni, Chaoqin Yu (2022). Influence of the gut microbiota on endometriosis: Potential role of chenodeoxycholic acid and its derivatives. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.954684
8. The role and challenges of intratumoral microbiota in colorectal cancer immunotherapy. frontiersin.org. https://www.frontiersin.org/articles/10.3389/fmicb.2024.1444105/full